抗炎药物及作用机理最新研究进展-王棋文

1,2,3,4(1.,　551700;2.,　551700;3.,　730050;4.,　730070):、。,,。,,、,。3。:;;;:S859.79　　　　　:A　　　　　:1671-7236(2010)03-0211-04　　(,2004)。,,。(、、)。2。,,。3。,,“-”、,、、。,,、。。1　(NSAIDs)、、、。。NSAIDsCOX-1COX-2,,:2009-11-04:(1981-),,,,,。:。:(2009129);(NSF90202009)。,(Smith,1996)。COX-1COX-2COXs2,60%。COX-1COX,,,,,、(Morita,1995);COX-2COX,,、,、(Penglis,2000)。、A,,COX-2PGs(Galipeau,2007)。NSAIDs,,。COX-1PGE2、PGI2,HCO-3,H+。NSAIDs,COX-1,PGs,、、(,2000)。,COX-2、(,2005),PGs,PGs,NSAIDs;COX/5-LOXNO,,,(Gaetano,2003;Stefano·211·　2010373,2001);NSAIDs,,(,2005)。2　、、,。(,2005)。2060(GR),,GC,:①GCGR,GRDNADNA;②GC-GRGC;③GRE,GC-GR,,(,1992)。:;;;;、、。(、、、)。3　3.1　中药抗炎作用　,,,。2,,,、、。,——(HPA),、。,、NO。3.1.1　对自由基类物质的抑制　(2001)EOS,(、、、、)。,GSH-PxSOD,MDA,EOS。,,EOS。(2005),,NO。(2005),(LPS)NO,LPSNO。3.1.2　抑制炎症相关细胞因子　,,IL-1、IL-6TNF-α,,。,,A2、、,,。TNF-α、IL-6、IL-8,-2(IL-2),,,(,2004)。,IL-2(sIL-2R)、IL-6(sIL-6R)TNF1(sTNFR-1)(,2004)。3.1.3　同时作用于炎症过程的多个环节　(2005),NOPGE2,C(CRP)(TNF-α)。(2004),CDCAcAMP、NO、PGE2。(RIMEC),LPS,RIMECNO、ET-1sICAM-1,LPSNOsICAM-1,NOsICAM-1,(,2007)。3.2　中药与抗炎免疫　、、,,,,。,。。3.2.1　免疫增强剂　,、(,2005)。,,·212·　2010373,:,,;,、、;,、;、;;;—;,——(,2004)。(2006),,,、。3.2.2　免疫抑制剂　,,。,、,、(,2001)。、、(LPS)LPSMF,、TNF,MFLPSTNF-α(,2006)。(2000),,,,。,。3.2.3　免疫调节剂　。,;;,;。“”(),。(2003)C,,PKC,C。(2003),,。,,,、。,(,2009)。4　,、。,、、,;,COX,、COX-2NSAIDs,COX-2,。COX-2,,,;,,。,,,。,,,,;,IL-10、IL-Ira,,(,2003)。1　,,,.[J].,2005(2):8～9.2　,,,.[J].,2004,26(3):12～·213·　201037314.3　.[J].,2009(3):24.4　,,,.[J].,2008,35(8):82～84.5　.[M].5.:,2001,891～894.6　,,,.E-[J].,2005,23(2):276～277.7　,,,.[J].,2000,31(2):211～213.8　,,,.[J].,2005,28(11):1002～1006.9　.[J].,2004(2):31～32.10,,.[J].,2003,19(2):138～142.11,.EOS[J].,2001,8(5):271～273.12,,.[M].1.:,1992,100～118.13,,.[J].(),2006,42(6):55～57.14.[M].6.:,2004,70.15,,,.[J].,2004,29(4):349～352.16.[M].6.:,2005,361～368.17,.[J].,2006,6:23～25.18,,,.[J].,2003,39(10):11～14.19,,,.[J].,2007,43(9):45～46.20,,,.8301[C].,2003,11(2):11～12.21.[D].:,2005.22.NSAID[J].,2000,16(1):15～18.23,,.[J].,2005,39(5):36～42.24,.()[J].,2004,8(7):441.25,,,.[J].,2005,30(15):1192～1194.26GaetanoG,DonatiMBC.Preventionofthrobosiandvascularinflammation:benefitsandlimitationsofselectiveorcombinedCOX-1,COX-2and5-LOXinhibitors.TrendinPharmacologicalSciences,2003,24(5):245～252.27GalipeauPC,LiX,BlountPL,etal.NSAIDsmodulateCD-KN2A,TP53andDNAcontentriskforprogressiontoesophage-aladenocarinoma.JPloSMED,2007,4(2):67.28MoritaI,SchindlerM,RegierMK,etal.DiefferentintracellularlocationsforprostaglandinendoperoxideHsynthase-1and-2.JBi-olChem,1995,270:10902～10908.29PenglisPS,ClelandLG,DemasiM,etal.DifferentialregulationofprostaglandinE2andthromboxaneA2productioninhumanmonocytes:implicationsfortheuseofCyclooxygenaseinhibi-tors.JImmunol,2000,165:1605～1611.30SmithWL,GaravitoRM,DewittDL,etal.Prostaglandinen-doperoxideHsynthases(cyclooxygenases)-land-2.JBiolChem,1996,271:33157～33160.31StefanoF,ElisabettaA,JeanlucB,eta1.Nitricoxide-releasingNSAIDs:areviewoftheircurrentstatus.DrugSafe,2001,24(11):801～811.RecentProgressontheStudyofAnti-inflammatoryDrugsanditsMechanismofActionWANGQi-wen1,SONGDe-rong2,LIJian-yong3,YUYuan-guang4(1.PrataculturalEcologicalInstituteofBijieUniversity,Bijie551700,China;2.InstituteofZootechnicsandVeterinaryScienceofBijieRegioninGuizhouProvince,Bijie551700,China;3.LanzhouInstituteofAnimalandVeterinaryPharmaceuticalScience,ChineseAcademyofAgriculturalSciences,Lanzhou730050,China;4.CollegeofVeterinaryMedicine,GansuAgriculturalUniversity,Lanzhou730070,China)　　Abstract:Anti-inflammatorydrugsincludeNSAIDs,SAIDsandtraditionalChinesemedicine.Becauseofitspoorselectiveandsignificantadverseeffects,theirclinicaluseislimited.Inrecentyears,accompanyingwithdeepenunderstandingofinflam-matorymechanisms,aswellastheextensiveapplicationofmolecularbiologytechniques,manynewanti-inflammatoryagentshavebeingcomeintomarket.Theresearchanddevelopmentofabove-mentionedmedicineswereexploredandanalyzedinthearticle.Keywords:NSAIDs;SAIDs;traditionalChinesemedicine;anti-inflammatorymechanism·214·　2010373